Potential mechanisms of FMT include direct interaction or competition between donor and recipient gut microbiota to achieve homeostasis, effect of donor microbiota on the host immunity and effect of microbiota on modulating host metabolism and physiology. Competitive niche exclusion is a plausible mechanism behind the therapeutic effects of FMT in the treatment of CDI by introducing competitors and/or modifying the diseased gut environment to the detriment of C. difficile. For example, introduction of non-toxigenic C. difficile strains can reduce the recurrence of CDI in subjects 1 . Another competition-based strategy harnessed by gut microorganisms is the production of bacteriocins 2 . Quorum sensing systems have also been detected in C. difficile and are known to affect toxin expression profiles in other coexisting microorganisms. FMT can alter host bile acid metabolism concomitant with alterations to gut microbiota composition. In CDI, a consistent metabolic signature with reduced primary bile acids and increased secondary bile acid production capacity has been reported after FMT. FMT restores Firmicutes phylum bacteria and secondary bile acid metabolism 3 , providing a prime example of FMT re-establishing normal gut microbiota and host metabolism. FMT also has the ability to restore gut microbiota and mucosal immunity and systemic immunity of the host. In mice models of colitis, FMT reduced colonic inflammation and initiated a simultaneous activation of different immune pathways, leading to interleukin (IL-10) production by innate and adaptive immune cells including CD4 + T cells, iNKT cells and Antigen Presenting Cells (APC), and reduced the ability of macrophages, monocytes and dendritic cells to present MHCII-dependent bacterial 
Figure 3: FMT preparations, formulations and delivery methods
For FMT administration, lower gastrointestinal (GI) delivery can be achieved through enema or colonoscopy, whereas upper GI delivery is through infusion via gastroscopy or via nasoenteric tubes. Oral capsules are non-invasive and is an ideal delivery method for FMT. Formulation to improve delivery, ensuring organism survival, and ensure colonization along the GI tract are needed 6 . An encapsulation technique based on a water-in-oil emulsion can provide better insulation of FMT material from GI environment 7 . One potential solution is the use of bile absorbent resins. The use of bile acid binding agents such as cholestyramine, when combined with Vcaps TM HPMC capsules, provided a 1700-fold increase in freeze-dried and rehydrated Lactobacillus casei in a simulated intestinal fluid containing 1% bile 8 . Alternatively, a layer-bylayer (LbL) encapsulation approach using muco-adhesive polysaccharides, chitosan and alginate, has been shown to improve cytoprotection, bioavailability, and engraftment of Bacillus coagulans in porcine and human intestines 9 . Capsule design content release is dependent on intestinal stimuli 10 . Other approaches include genetic engineering, for example Escherichia coli engineered to bind to colorectal cancer cell receptors and catalyse production of molecules with anticancer activity 11 . This novel approach can be considered for FMT if constituent strains that contribute to clinical efficacy are identified. They can then be engineered to improve binding and colonization in the gut of FMT recipients. 
